• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Walgreens Boots Alliance Early-Settles Certain Prepaid Variable Share Forward Transactions and Sells Related Shares of Cencora For Approximately $300 Million of Proceeds

    2/6/25 8:30:00 PM ET
    $COR
    $WBA
    Other Pharmaceuticals
    Health Care
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $COR alert in real time by email

    Transaction Highlights

    • Walgreens Boots Alliance announces early settlement of certain prepaid variable share forward transactions with respect to shares of Cencora for delivery of an aggregate 6.1 million shares
    • Concurrent with the early settlement, the Company executed a sale of the remaining 1.3 million shares of Cencora pledged under the early settled contracts. The Company receives approximately $300 million from the early settlement and the concurrent sale of shares
    • Following today's early settlement, the Company owns approximately 12.6 million shares of Cencora pledged under the remaining prepaid variable share forward contracts, which have the potential to provide additional cash proceeds at maturity. These remaining prepaid variable share forward contracts are mainly scheduled to mature during March, June and September of calendar year 2025.
    • Use of proceeds will primarily be for debt paydown, as the Company proactively seeks to address its debt maturities in fiscal year 2026, and for general corporate purposes

    Walgreens Boots Alliance, Inc. (NASDAQ:WBA) has agreed to the early settlement of certain prepaid variable share forward transactions it had previously entered into with various financial institutions, with respect to shares of Cencora, Inc. (NYSE:COR). Under these transactions, the Company had previously received cash payments in an aggregate amount of approximately $1.1 billion on or about the dates of first entering into them. The transactions were scheduled to mature during March and June of calendar year 2026.

    As part of the early settlement of the transactions prior to their scheduled maturities, WBA will deliver to the financial institutions an aggregate of approximately 6.1 million shares of Cencora, while paying a net aggregate cash payment of approximately $20 million. The transaction fulfills the Company's obligations to deliver shares at a future date to each financial institution participating in the early settlement. These contracts have accreted cash value to the Company as a result of participation in the appreciation of Cencora's stock since entering the transactions in 2023. The early settlement together with the concurrent share sale realizes the embedded cash value that exists in the prepaid variable share forwards.

    Concurrent with these early settlements, WBA today announced that it has sold shares of Cencora common stock in an unregistered block trade pursuant to Rule 144 for proceeds of approximately $265 million, and has sold additional shares in a share repurchase by Cencora for additional proceeds of approximately $50 million.

    Proceeds to WBA will be used primarily for debt paydown and general corporate purposes. The proceeds from these transactions as well as other actions, including the recent suspension of the dividend, further help position the Company to address its upcoming debt maturities in fiscal 2026.

    Walgreens Boots Alliance's ownership of Cencora's common stock has decreased from approximately 10 percent to approximately six percent.

    The sale has no impact to the long-term partnership between the two companies. Walgreens Boots Alliance remains fully committed to the strategic, mutually beneficial relationship with Cencora, which has been a strong and trusted partner since 2013. Chief Operating Officer, International of Walgreens Boots Alliance, Ornella Barra, will continue to serve on Cencora's Board of Directors.

    About Walgreens Boots Alliance

    Walgreens Boots Alliance (NASDAQ:WBA) is an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, with a 175-year heritage of caring for communities.

    A trusted, global innovator in retail pharmacy with approximately 12,500 locations across the U.S., Europe and Latin America, WBA plays a critical role in the healthcare ecosystem. Through dispensing medicines, improving access to pharmacy and health services, providing high quality health and beauty products and offering anytime, anywhere convenience across its digital platforms, WBA is shaping the future of healthcare in the thousands of communities it serves and beyond.

    WBA employs approximately 311,000 people, with a presence in eight countries and consumer brands including: Walgreens, Boots, Duane Reade, No7 Beauty Company and Benavides. The Company is proud of its contributions to healthy communities, a healthy planet, an inclusive workplace and a sustainable marketplace. In fiscal 2024, WBA scored 100% on the Disability Equality Index for disability inclusion.

    More Company information is available at www.walgreensbootsalliance.com.

    (WBA-GEN)

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250206482504/en/

    WBA Media Relations

    USA / Jim Cohn, [email protected]

    WBA Investor Relations

    Eric Wasserstrom, [email protected]

    Get the next $COR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $COR
    $WBA

    CompanyDatePrice TargetRatingAnalyst
    Cencora Inc.
    $COR
    6/3/2025$337.00Equal Weight → Overweight
    Wells Fargo
    Walgreens Boots Alliance Inc.
    $WBA
    2/28/2025$11.00 → $9.00Hold → Sell
    Deutsche Bank
    Cencora Inc.
    $COR
    12/4/2024$280.00Outperform
    Mizuho
    Cencora Inc.
    $COR
    9/18/2024$275.00 → $245.00Buy → Neutral
    BofA Securities
    Walgreens Boots Alliance Inc.
    $WBA
    2/26/2024$23.00Market Perform
    Leerink Partners
    Cencora Inc.
    $COR
    2/26/2024$261.00Outperform
    Leerink Partners
    Walgreens Boots Alliance Inc.
    $WBA
    2/20/2024Hold → Reduce
    HSBC Securities
    Walgreens Boots Alliance Inc.
    $WBA
    1/3/2024$21.00Underweight
    Barclays
    More analyst ratings

    $COR
    $WBA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • September 12, 2023 - FDA Issues Warning Letters to Firms Marketing Unapproved Eye Products

      For Immediate Release: September 12, 2023 The U.S. Food and Drug Administration has issued warning letters to eight companies for manufacturing or marketing unapproved ophthalmic drug products in violation of federal law. These warning letters are part of the agency’s ongoing effort to protect Americans from potentially harmful ophthalmic products. Eye products addressed in the eight warning letters are illegal

      9/12/23 10:44:21 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $COR
    $WBA
    SEC Filings

    See more
    • SEC Form 11-K filed by Cencora Inc.

      11-K - Cencora, Inc. (0001140859) (Filer)

      6/17/25 4:33:24 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • SEC Form DEFA14A filed by Walgreens Boots Alliance Inc.

      DEFA14A - Walgreens Boots Alliance, Inc. (0001618921) (Filer)

      6/17/25 4:05:47 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form DEFA14A filed by Walgreens Boots Alliance Inc.

      DEFA14A - Walgreens Boots Alliance, Inc. (0001618921) (Filer)

      6/13/25 4:05:18 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $COR
    $WBA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • EVP, Global CLO & Corp. Sec. Minnix Lanesha covered exercise/tax liability with 19,135 shares, decreasing direct ownership by 5% to 348,093 units (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      6/3/25 9:16:29 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • EVP, President U.S. Healthcare Langowksi Mary covered exercise/tax liability with 40,304 shares, decreasing direct ownership by 8% to 494,295 units (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      6/3/25 9:12:39 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • EVP, Global Chief HR Officer Burger Elizabeth covered exercise/tax liability with 16,495 shares, decreasing direct ownership by 5% to 303,875 units (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      6/3/25 9:08:21 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $COR
    $WBA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Executive Chairman of Board Pessina Stefano sold $9,163,161 worth of shares (832,258 units at $11.01) and bought $9,163,161 worth of shares (832,258 units at $11.01), decreasing direct ownership by 56% to 657,308 units (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/29/25 8:49:21 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Durcan Dermot Mark bought $109,290 worth of shares (500 units at $218.58), increasing direct ownership by 2% to 21,876 units (SEC Form 4)

      4 - Cencora, Inc. (0001140859) (Issuer)

      5/29/24 4:02:27 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Bhandari Inderpal S bought $54,150 worth of shares (3,000 units at $18.05) (SEC Form 4)

      4 - Walgreens Boots Alliance, Inc. (0001618921) (Issuer)

      4/15/24 5:45:26 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $COR
    $WBA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cencora upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded Cencora from Equal Weight to Overweight and set a new price target of $337.00

      6/3/25 7:24:57 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Walgreens Boots Alliance downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded Walgreens Boots Alliance from Hold to Sell and set a new price target of $9.00 from $11.00 previously

      2/28/25 7:36:45 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Mizuho resumed coverage on Cencora with a new price target

      Mizuho resumed coverage of Cencora with a rating of Outperform and set a new price target of $280.00

      12/4/24 7:30:44 AM ET
      $COR
      Other Pharmaceuticals
      Health Care

    $COR
    $WBA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Walgreens and KFF's Greater Than Campaign to Offer Free HIV/STD Testing in Stores on June 27

      More than 415 local health departments and community organizations mobilize across the country for largest-ever National HIV Testing Day event Walgreens and Greater Than HIV/STDs, a public information campaign from KFF, are joining with health departments and community organizations to provide free rapid HIV, syphilis and hepatitis C testing at more than 575 Walgreens stores on June 27 for the nation's largest National HIV Testing Day (NHTD) event. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612760766/en/ With more than 415 local testing partners in nearly all states, Washington, D.C. and Puerto Rico, this year's activat

      6/12/25 9:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • LiveRamp and Walgreens Advertising Group Deliver Business Growth for Advertisers Through Robust Data Collaboration Partnership

      WAG advertisers can now accelerate audience creation, activation, and measurement with flexibility and speed LiveRamp (NYSE:RAMP), the leading data collaboration partner, today announced it is powering Walgreens Advertising Group's (WAG) clean room solution. The partnership enables WAG, the retail media division of Walgreens, to increase access to its first-party data at speed, scale audience insights, and offer more transparency and control to advertisers. This enables brands to enhance media measurement across all platforms in the digital ecosystem and improve ROI with faster time-to-value. LiveRamp's data collaboration network enables WAG to unlock new insights, accelerate performanc

      6/11/25 5:30:00 AM ET
      $RAMP
      $WBA
      EDP Services
      Technology
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Cencora Elects Lori J. Ryerkerk to Its Board of Directors

      Cencora, Inc. (NYSE:COR) today announced that its Board of Directors has elected Lori J. Ryerkerk as a new independent director, effective June 1, 2025. "Ms. Ryerkerk's experience in complex, global supply chains will further strengthen the Board's expertise as we continue supporting the company's long-term growth. Her appointment reflects the Cencora Board's ongoing commitment to leaders who can help us contribute to driving stakeholder value," said Mark Durcan, Lead Independent Director. "Lori's experience as a public company CEO, leading a global specialties chemical company with extensive operations and logistics, will bring valuable insight as we execute against our strategy and bu

      5/28/25 7:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care

    $COR
    $WBA
    Financials

    Live finance-specific insights

    See more
    • Cencora Reports Fiscal 2025 Second Quarter Results

      Revenue of $75.5 billion for the Second Quarter, a 10.3 percent Increase Year-Over-Year Second Quarter GAAP Diluted EPS of $3.68 and Adjusted Diluted EPS of $4.42 Adjusted Diluted EPS Guidance Range Raised to $15.70 to $15.95 for Fiscal 2025 Cencora, Inc. (NYSE:COR) reported that in its fiscal year 2025 second quarter ended March 31, 2025, revenue increased 10.3 percent year-over-year to $75.5 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.68 for the second quarter of fiscal 2025 compared to $2.09 in the prior year second quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described

      5/7/25 6:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Walgreens Boots Alliance Reports Fiscal 2025 Second Quarter Results

      Second quarter financial results Second quarter loss per share1 was $3.30 compared to loss per share of $6.85 in the year-ago quarter. Second quarter results include $4.2 billion of non-cash impairment charges attributable to WBA, net of tax and non-controlling interest, related to goodwill, intangible and other long-lived assets primarily at U.S. Retail Pharmacy and VillageMD, and $1.0 billion of after-tax gains related to asset monetization activities. Adjusted earnings per share (EPS)2 was $0.63 compared to adjusted EPS2 of $1.20 in the year-ago quarter. The decline in adjusted EPS2 was primarily driven by prior year adjusted effective tax benefit2, lower U.S. retail sales and prior

      4/8/25 7:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Cencora Announces Date and Time for Second Quarter Fiscal 2025 Earnings Release

      Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Second Quarter of Fiscal 2025 on Wednesday, May 7, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on May 7, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the call via

      3/28/25 7:00:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care

    $COR
    $WBA
    Leadership Updates

    Live Leadership Updates

    See more
    • Cencora Expands Enterprise Leadership Team with Two Senior Appointments

      Francois Mandeville Named Executive Vice President, Strategy and M&A Pawan Verma Appointed Executive Vice President, Chief Data and Information Officer Cencora, Inc. (NYSE:COR) today announced the appointment of Francois Mandeville as Executive Vice President, Strategy and M&A, and Pawan Verma as Executive Vice President, Chief Data and Information Officer. Both leaders will join Cencora's enterprise leadership team, bringing their extensive experience and expertise to help advance the company's pharmaceutical-centric strategy and drive growth for Cencora and its customers. "We're thrilled to welcome Francois and Pawan to Cencora's leadership team," said Bob Mauch, President and Chief Ex

      11/4/24 8:30:00 AM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Walgreens Appoints Jason Stenta as SVP and Chief Commercial Officer

      Stenta will lead B2B commercial growth strategy as the company strengthens its role as the first choice for community pharmacy and health services in the U.S. Walgreens, an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, today announced the appointment of Jason Stenta as SVP and chief commercial officer. In this new role, Stenta will lead the company's commercial growth strategy, driving development and commercialization of B2B healthcare services built on the company's core assets, and enhancing partnerships with payers, health system providers and life sciences companies. This press release features multimedia. View the full release

      10/7/24 8:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Walgreens Appoints Two New Leaders to its Retail and Customer Experience Team

      Names Tracey Koller as Chief Merchandising Officer and Sharmila Sudhakar as Group Vice President and Head of Digital Commerce Walgreens, the leading independent retail pharmacy and healthcare provider, today announced two key leadership appointments: Tracey Koller, senior vice president and chief merchandising officer, and Sharmila Sudhakar, group vice president and head of Walgreens digital commerce. The company believes these new appointments will significantly contribute to its efforts with regard to the turnaround of the business as the company focuses on enhancing the front of store and omnichannel experience for its customers while driving in-store efficiencies. This press release

      8/16/24 9:00:00 AM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $COR
    $WBA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Cencora Inc.

      SC 13G/A - Cencora, Inc. (0001140859) (Subject)

      11/14/24 1:22:34 PM ET
      $COR
      Other Pharmaceuticals
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Walgreens Boots Alliance Inc.

      SC 13G/A - Walgreens Boots Alliance, Inc. (0001618921) (Subject)

      10/18/24 12:45:41 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Amendment: SEC Form SC 13D/A filed by Walgreens Boots Alliance Inc.

      SC 13D/A - Walgreens Boots Alliance, Inc. (0001618921) (Filed by)

      8/20/24 4:05:58 PM ET
      $WBA
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples